Few drugs have a better claim on the word remarkable. Ivermectin came out of a soil sample collected near a golf course in Japan, won its discoverers the Nobel Prize in Physiology or Medicine in 2015, and has been given away by the billion for nearly forty years. It is also the subject of more confident nonsense than any other compound in circulation.
Those two things are connected. The honest account of ivermectin is more interesting than either the promotional version or the dismissive one, and it turns on a single number.
What it has already done
Satoshi Ōmura isolated the bacterium; William Campbell found what its compounds did to parasites. The drug that resulted, ivermectin, is on the WHO Model List of Essential Medicines, and its record in parasitic disease is close to unmatched.
River blindness. Onchocerciasis blinded and disfigured millions across west and central Africa and parts of Latin America. In 1987 Merck committed to donating ivermectin for the disease for as long as needed, anywhere it was needed — the Mectizan Donation Program, still the largest ongoing drug donation in medical history, running to billions of treatments. Transmission of the parasite has since been verified as eliminated in Colombia, Ecuador, Mexico and Guatemala.
Lymphatic filariasis. The disease that causes elephantiasis is being driven down by mass drug administration in which ivermectin is a core component, increasingly in a three-drug combination that clears the parasite far faster than earlier regimens.
Strongyloidiasis. Ivermectin is the treatment of choice. This matters more than its profile suggests: a Strongyloides infection can sit quietly for decades and then, when someone is given corticosteroids or otherwise immunosuppressed, convert to hyperinfection that is frequently fatal. Screening and treating before immunosuppression saves lives that would never appear in a statistic.
Scabies. Oral ivermectin treats it, and mass administration in high-burden communities has cut not only scabies but the impetigo that follows from scratching — a trial in Fiji found large reductions in both. Skin infection is a major driver of downstream kidney and heart disease in those settings, so the benefit runs well past the itch.
None of this is fringe or contested. It is the reason the drug is on the essential medicines list, and it is the single largest true item on any list of ivermectin's benefits.
Why the literature makes it look like it does everything
Search the research databases and you will find ivermectin reported to kill cancer cells, suppress inflammation, inhibit viruses, improve markers of glucose and lipid metabolism, protect the liver, and encourage nerve regeneration. These papers exist. They are not fabricated, and the people who cite them are not making them up.
The catch is in the methods section. Almost all of these findings come from cell culture, and almost all of them require ivermectin at concentrations in the micromolar range.
Here is the number the whole subject turns on. A standard approved oral dose produces a peak plasma concentration of roughly 20 to 80 nanograms per millilitre — on the order of 0.02 to 0.09 micromolar. The concentrations at which ivermectin does the interesting things in a dish are typically one to two orders of magnitude higher than anything an approved dose puts in your blood.
You cannot simply take more. Ivermectin is safe at its approved doses precisely because P-glycoprotein pumps it back out at the blood–brain barrier, keeping it away from mammalian nerve tissue while it acts on the parasite's glutamate-gated chloride channels. Push the dose high enough and that protection is overwhelmed. The safety margin is real, and it is not infinite.
So the enormous preclinical literature is not fake. It is measuring what a molecule does to cells at concentrations a person cannot reach by swallowing a tablet. That one fact explains nearly every overstated claim made about this drug, and it should be applied before any of them.
The exception that proves the rule
There is one place where the concentration problem disappears, and it is instructive: topical ivermectin 1% cream is an approved, effective treatment for papulopustular rosacea.
It works, and it works partly through the anti-inflammatory activity that the cell-culture papers describe. The reason is that you are applying it directly to the tissue you want to treat, achieving a local concentration that no oral dose could produce systemically.
This is the honest version of "ivermectin has anti-inflammatory effects". The effect is real. Delivering it to a joint, a gut wall, or a coronary artery at a concentration that would do anything is a different problem, and it has not been solved.
COVID-19: what actually happened
The COVID story is worth telling accurately, because it is a clean illustration of how evidence is supposed to work — and of how it can be corrupted.
The starting signal was legitimate. In 2020 an Australian group reported that ivermectin reduced SARS-CoV-2 RNA in cell culture by several thousand-fold. That was a real result and a perfectly good reason to investigate further.
Then pharmacology raised its hand. The concentration used in that experiment was several micromolar. Modelling published shortly afterwards pointed out that achieving it in human plasma would require doses far above the approved range. The finding was true and the route to a human treatment was not obvious.
Then the evidence base was poisoned. Several of the studies that made the early meta-analyses look positive turned out to be fraudulent. A widely circulated Egyptian trial was withdrawn after data problems and plagiarism were found in it; an Iranian trial was retracted. These were not marginal papers — they carried much of the weight in the pooled analyses that were being shared as proof. When they were removed, the apparent effect largely went with them.
Then the real trials were done. Large, randomised, independently funded trials — TOGETHER in Brazil, ACTIV-6 and COVID-OUT in the United States, PRINCIPLE in the United Kingdom — tested ivermectin properly. None found a reduction in hospitalisation or death. PRINCIPLE found a small improvement in self-reported time to recovery, without any effect on the outcomes that matter clinically.
That is the answer. It is not a cover-up, and it did not depend on anyone's opinion of vaccines.
Why this strengthens the argument about cheap drugs
This site argues regularly that off-patent compounds go under-investigated because nobody can profit from the trial that would settle them. That argument is correct and it is well documented in the pharmacoeconomics literature.
Ivermectin and COVID is not an example of it, and pretending otherwise damages the case everywhere else. Here the trials were funded, were run, and were negative. Keeping those two situations distinct — "nobody has paid for the study" versus "the study was done and the answer was no" — is what makes the first claim credible when it genuinely applies. Blur them, and a critic gets to dismiss the whole argument by pointing at this one case.
Where the real promise is now
If you want a genuinely exciting current use for ivermectin, it is not any of the usual list items. It is malaria.
Ivermectin in a person's blood is lethal to the mosquitoes that bite them. Treat enough people in a community and you shorten the lifespan of the local Anopheles population, which cuts transmission by a route no bed net or vaccine touches. This is being tested in large field trials in Africa, funded by public health bodies rather than by anyone selling anything.
It may or may not work at scale — that is what the trials are for. But it is a real, live, well-designed line of research, and it is a better argument for taking this drug seriously than any of the claims usually made on its behalf.
Cancer, stated precisely
Ivermectin kills cancer cells in culture and slows tumour growth in some animal models, at the micromolar concentrations described above. There is early interest in whether it interferes with drug-resistance pumps in tumour cells.
That is the whole of it. There is no phase 3 evidence, no established human protocol, and no basis for using it as a cancer treatment. Nobody should delay, replace or decline oncological care on the strength of this literature, and the honest description of it is "preclinical" — every time, without exception.
Safety, honestly
At approved doses and for approved indications, ivermectin's safety record across billions of treatments is genuinely excellent. But "no adverse effects" is not true of any drug, and it is not true of this one.
- In regions where Loa loa is endemic, treating someone with a heavy parasite load can trigger a severe and sometimes fatal encephalopathy. This is the reason mass administration programmes map that parasite before they start.
- Neurological toxicity appears at high doses, and disproportionately in people with variants affecting the P-glycoprotein transporter.
- Ivermectin is metabolised in the liver, principally by the CYP3A4 enzyme. The claim that it bypasses the liver is simply wrong, and it matters, because hepatic metabolism is where its interactions with other drugs come from.
- Veterinary formulations are concentrated for animals many times human body weight and have caused real poisonings.
What it comes to
Ivermectin is one of the most consequential medicines of the last half-century, and the case for it does not need any help. River blindness is gone from four countries. Scabies and the kidney disease that trails it are falling in places that ran mass treatment. Strongyloides screening prevents deaths that never get counted. A cream made from it treats a skin condition that used to have poor options. And it may yet turn out to kill malaria mosquitoes from inside the people they bite.
None of that requires it to cure cancer, reverse a vaccine, or work against a virus that four large trials say it does not touch. The extraordinary claims are not a bonus on top of the real story. They are the reason a lot of people never hear the real story at all.
No comments yet